Please begin your Research here:
http://www.arrayit.com and http://finance.yahoo.com/q?s=ARYC.OB
We are extremely excited and proud to bring to you our next MEGA Pharma FDA play,ARYC.OB!
Arrayit Corp. currently trades on the OTC:BB at .80. There is alot to read here but we urge you to read everything for this potentially HUGE opportunity.
When we discovered Arrayit Corp. and began our research, we could not believe the upside potential that exists in this investment! The first thing that obviously struck us was that the current PPS is BELOW ONE DOLLAR! First and foremost I would like to stress that we are looking at ARYC as a LONG-TERM FDA Play. At this level, we believe that we may see gains of over 1,000% in the future especially with FDA Approval!
You may think this is just "newsletter chatter", however, given the extraordinary rise of FDA plays such as our recent pick POZN, DNDN, BIEL, HEB, and more, this is clearly a possibility. We will be spotlighting this pick in the same way we have been spotlighting our last FDA play, POZN, which recieved FDA Approval on Friday and is on its way to new heights.
The best part is we are bringing this pick to you at the GROUND FLOOR. We believe in a few weeks/months, you will be able to say, "I got in on the Mega Stock Picks Alert at the ground floor" when new investors are scouring for shares well above your first entry. Much of the investment community does not know about this company yet and whats in store for the next few months. They are all looking for the next DNDN, and we believeWE HAVE FOUND IT!
ABOUT ARYC
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Arrayit now offers over 650 products to a customer base of more than 10,000 clinics and research facilities, and more than 5,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises.
December 10, 2009 Arrayit announced it would enter the diagnostics markets with its first diagnostics product, OvaDx™, A pre –symptomatic Ovarian Cancer test using its proprietary patented microarray technology. Upon FDA approval, OvaDx™ should have rapid adoption, accelerating revenue and earnings growth. Conservative estimates are for revenues that could reach 1 billion within 5 years for this test alone. Arrayit is working on other Pre-Symptomatic tests for other diseases such as Parkinson, Prostate and Breast cancer. Arrayit’s Biomarker Discovery and Platform tools business are areas of increasing revenue and earnings growth potential when further capital is raised. This opportunity exists based on its excellent science reputation and its position as one of the largest installed micro-array platforms in the world. Arrayits Patented Micro-Array platform has significant scalability advantages over the competition creating cost and data accuracy for diagnostic tests and research Pharma.
First of all, ARYC is a very low floater that has a market cap of about $18 MM and already generating revenue and profitable on a cash flow operational basis. This company has actually been around for 17 years but the reason many on the Street are unaware of this gem is because they just went public via a reverse merger last year.
As mentioned in the above description, ARYC is the proprieter of OvaDX(TM), a pre-symptomatic Ovarian Cancer test using it's PATENTED microarray technology.
ARYC's OvaDX Pre-Symptomatic Ovarian Cancer Test will be the FIRST comprehensive diagnostic screen for this cancer in the market. OvaDX uses approximately 100 proteomic biomarkets in a microarray format to identify molecular beacons of ovarian cancer that accumulate in the bloodstream as a result of the body's natural immune response to developing ovarian tumors.
Arrayit Corp owns the LARGEST installed Micro-Array platform in the world. This platform base is about to be leveraged by upcoming announcements regarding major discoveries bringing upon large consumable orders on the platform from major Pharmaceutical Companys and creating a rush by other Pharma companies to get similar results!
This company is being run by the best and the brightest. Please do some research on ARYC's President, Mark Schena at the below links:
We believe this FDA play is a NO-BRAINER! Here are a few points why:
- ARYC is ready to make FDA application for IVD MIA Test for Ovarian Cancer, OvaDX, viaDOCRO to submit the test. Please see this link on DOCRO. DOCRO has a 99% success rate with the FDA and has steered nearly 100 In Vitro Diagnostic (IVD) clinical trials through FDA Approval in the past 12 years!
- Vermillion (VRML) and Agendia (Netherlands based www.agendia.com), Arrayit Corp. Clients, have both already been approved by the FDA via ARYC's microarray method!
- This test qualifies for FAST TRACK APPROVAL STATUS under the UNMET medical need waiver which means there is no requirement for the standard Phase I, II, and III test approvals!
- ARYC is working on other Pre-Symptomatic tests for other diseases such as Parkisons, Prostate, and Breast Cancer. ARYC's patented Micro-Array technology may become the STANDARD for the discovery of all diseases!
- ARYC has positioned itself to announce alliances with Major Pharmaceutical companiesfor potential revenue orders and further validation of it's platform. Conservative estimates are for revenues to exceed 1 BILLION DOLLARS within 5 years for this test alone!
John Howell, CEO of Arrayit Diagnostics, Inc., added, “With plans to market the test at a cost of approximately $350 per test kit and presuming we achieve our predetermined time-to-market objectives, we are confident that revenue of $4-$5 million is an attainable sales goal for 2010. Moreover, given that we estimate the total market for a viable early stage ovarian cancer screening test in the U.S., Japan and Europe could collectively represent use of up to 175 million kits per year; beyond 2010, annual revenues for Arrayit Diagnostics could ultimately reach into the hundreds of millions, and perhaps even billions, of dollars.”
There is SO MUCH more to be said about the incredible investment potential of ARYC. We will continue to provide updates over the next few weeks/months. We STRONGLY URGE you all to do your own further DD on this company and consider the HUGE upside potential.
Fast-Track FDA Decision via DOCRO, an already APPROVED technology, Major Pharma Alliances, a potential multi-disease product, and an extremely low float....there is NO WAY we will be seeing ARYC below a dollar again!
No comments:
Post a Comment